NCT03432793View on ClinicalTrials.gov

Drug-Drug Interaction (DDI) Study for TD-9855

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

April 21, 2018

Study Completion Date

April 21, 2018

Conditions
Drug Drug Interaction (DDI)
Interventions
DRUG

TD-9855

oral tablet, QD

DRUG

Fluvoxamine

oral tablet, QD

DRUG

Itraconazole

oral tablet solution, QD

DRUG

Caffeine

oral solution, single dose

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY